Scilex Holding Company Completes Key Steps for Merger

Key Announcement from Scilex Holding Company

Scilex Holding Company, an innovative player in the pharmaceutical sector, has made significant strides in its ongoing merger processes. The company has announced that the registration statement on Form S-4, related to its proposed business combination with Semnur Pharmaceuticals, has been officially declared effective by the U.S. Securities and Exchange Commission (SEC).

Business Combination Details

The planned merger involves Denali Capital Acquisition Corp., a special purpose acquisition company, and Semnur Pharmaceuticals, Inc., which is a majority-owned subsidiary of Scilex. This strategic move is aimed at enhancing Scilex's position in the non-opioid pain management market, which is crucial for addressing acute and chronic pain along with various neurodegenerative conditions.

Extraordinary Meeting Scheduled

To further facilitate this merger, Denali has scheduled an extraordinary general meeting for its shareholders. This important meeting will take place soon and is essential for obtaining approval required for the business combination. Shareholders of Denali will receive information regarding the voting process and details about the meeting.

Future Plans Post-Merger

Upon successful completion of the merger, Scilex plans to rename the combined entity to Semnur Pharmaceuticals, Inc. This indicates a strategic alignment with Semnur’s product portfolio, which includes innovative non-opioid therapies designed for pain relief.

Application for Nasdaq Listing

As part of the closing process, the combined company will be seeking a listing on The Nasdaq Stock Market LLC. However, approval of this application is still pending, and there remains uncertainty regarding the compliance with listing standards.

Innovative Product Pipeline

Scilex is dedicated to expanding its influence in the pharmaceutical industry by placing a strong emphasis on developing and commercializing non-opioid pain management products. Their existing well-established products include ZTlido® for neuropathic pain, ELYXYB® for migraine treatment, and Gloperba® for gout. These products highlight Scilex's commitment to addressing unmet medical needs in pain management.

Research and Development Focus

Beyond their established products, Scilex is also advancing several promising product candidates. These candidates include SP-102 (SEMDEXA), a formulation undergoing rigorous clinical trials for managing chronic pain, and SP-103, a next-generation topical solution for acute pain management. These advancements signify Scilex’s goal of providing effective alternatives to traditional opioids.

Headquarters and Contact Information

Scilex is headquartered in Palo Alto, California, and is focused on innovation and enhancing patient outcomes through its extensive research and development.

Contact Details:
Investors and Media
Scilex Holding Company
960 San Antonio Road
Palo Alto, CA 94303
Office: (650) 516-4310
Email: investorrelations@scilexholding.com
Website: www.scilexholding.com

Frequently Asked Questions

What is the purpose of the business combination?

The business combination aims to expand Scilex's capabilities in the pain management market and enhance its product offerings through Semnur Pharmaceuticals.

When is the shareholders' meeting for Denali?

An extraordinary general meeting will be held for Denali Capital Acquisition Corp. shareholders to vote on the proposed merger.

What products does Scilex currently offer?

Scilex markets ZTlido®, ELYXYB®, and Gloperba®, targeting various pain management needs.

Where is Scilex based?

Scilex Holding Company is located in Palo Alto, California.

How does the merger impact shareholders?

The merger is designed to enhance shareholder value by strengthening Scilex's position in the pharmaceutical industry through innovative products.

About The Author

Hi there I'm 38-year-old author and financial consultant Owen Jenkins. Having worked in the financial sector for more than ten years, I am well-versed in the subtleties and complexity that mold our financial environment. Following a degree in finance, I worked in a number of financial institutions honing my abilities in market analysis, financial planning, and investment strategies.

My love is teaching others about investing and personal finance. My goal in writing many books and articles has been to demystify financial ideas and give readers the information they need to make wise financial decisions. I write with a direct, useful style that emphasizes doable suggestions for daily living.

Along with writing, I lead webinars and seminars where I impart knowledge on how to successfully negotiate the financial world. I also write for financial journals and show up as a guest expert on financial news programs a lot. Whether they are new to investing or want to improve their approach, my mission is to enable people to take charge of their financial futures.

Beyond work, I like to hike, play the guitar, and spend time with my family. I think that balance is crucial and want to encourage people to strike a balance between their financial aspirations and their hobbies. I want to help people succeed and achieve financial security through my work, so having a good influence.

Contact Owen Jenkins privately here. Or send an email with ATTN: Owen Jenkins as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.